Branded Generics Escape Indian Trade Margin Limits
This article was originally published in PharmAsia News
Generic drugs with brand names in India could be excluded from the government's proposal to restrict trade margins. The exclusion would cover drug makers such as Cadita Healthcare, GlaxoSmithKline, Nicholas Piramal and Ranbaxy, all of which sell generics under brand names rather than chemical names. Those brand names place the drugs in another category under Indian law. Makers of the branded generics allow retail pharmacies a trade margin as high as 29 times the manufactured price. (Click here for more
You may also be interested in...
In an open letter to the European Commission, Parliament and Council presidents, more than 400 cosmetics companies and animal-rights groups accuse the European Chemicals Agency of effectively “shredding” the animal testing ban on cosmetics by requiring testing for certain chemicals under REACH.
Pink Sheet reporters and editors look at the UK MHRA’s surprising approval of the Pfizer/BioNTech coronavirus vaccine, as well as the US reaction, and discuss President-elect Joe Biden’s potential US FDA commissioner nominees.
Divesting the heart valve division will allow LivaNova to focus more resources on its neuromodulation, cardiopulmonary and circulatory support businesses.